AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 282 min read$VVOS

Vivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular Partnership

Vivos Therapeutics (VVOS) partners with South Palm Cardiovascular Associates to establish a Sleep & Airway Medicine Center in Florida. Vivos will hold 75% of the new entity, AIM Florida, with plans to start operations in Q1 2027. The center aims to treat 250 patients monthly, generating up to $6M annual revenue with 30%+ margins. SPCVA will expand referrals for sleep disorder-related conditions. VVOS stock is currently at $0.25, up 0.58%.

Original reporting
rttnews.com
Published Aug 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VVOS
Bullish
medium confidence
Mentioned
$VVOS
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$VVOSBullishLow
01

Why it matters

The agreement introduces a new clinic model that could diversify Vivos' revenue base, though the financial impact is modest relative to the company's market cap.

02

Market read

First disclosure of a partnership that adds a new revenue line for a micro‑cap, with limited immediate market impact.

03

What to watch

Potential dependence on referral volume from SPCVA and the need for successful payer enrollment.

Relevance 5/10Novelty 6/10Timing: first‑report of partnership, revenue expected Q1 2027

Background

Vivos Therapeutics (VVOS) focuses on devices for obstructive sleep apnea. The collaboration with South Palm Cardiovascular aims to create a physician‑aligned management services organization.

Company-level read

Ticker impact

$VVOSBullishMedium confidence
Context

Vivos Therapeutics announced a definitive collaboration with South Palm Cardiovascular to launch a Sleep & Airway Medicine Center, projecting up to $6 million annual revenue.

Expected impact

Modest upside pressure as investors price in the $6 M revenue outlook.

Evidence & confidence

The deal is the first disclosed partnership for Vivos and adds a tangible revenue source, but the scale is limited for a micro‑cap.

Market effects

Sector

May signal growing demand for integrated sleep‑apnea services within cardiovascular care.

Regional

Adds a new specialty clinic in South Florida, modest local healthcare market effect.

Global

Limited to niche medical‑device segment; unlikely to affect broader markets.

Counterpoint

What could challenge this read

The projected $6 M revenue is modest and may be delayed by regulatory or payer hurdles, limiting upside.

Key entities

  • company
    Vivos Therapeutics, Inc.

    Medical device and healthcare services firm developing sleep‑apnea solutions.

  • company
    South Palm Cardiovascular Associates

    Physician‑owned cardiology practice partnering with Vivos.

Read at source← All news

Related articles

OCT 19
$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

stocktitan.net3 min
OCT 19
$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

SEC EDGAR 8-K2 min
JUN 30
$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

manilatimes.net4 min
JUN 10
$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

rttnews.com4 min
OCT 19
$CRWVMed

BNP Paribas Lowers CoreWeave (CRWV) Price Target to $117 Amid In

BNP Paribas cut CoreWeave's (CRWV) price target from $169 to $117, citing concerns over investor confidence and rising financing costs. The company's P/S ratio is 4.26, below its historical median, and its GF Score is 8/100, indicating financial health challenges. Insider selling totaled $5.88 billion. CoreWeave operates in cloud infrastructure for AI, with a market cap of $33.71 billion.

gurufocus.com2 min